Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: A survey of oncologists

Oncologist

Volumn 14, Issue 9, 2009, Pages 883-890

  Hurria, Arti ^a   Wong, F Lennie ^a   Pal, Sumanta ^a   Chung, Cathie T ^a   Bhatia, Smita ^a   Mortimer, Joanne ^a   Somlo, George ^a   Hurvitz, Sara ^b   Villaluna, Doojduen ^a   Naeim, Arash ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant treatment; Elderly; Geriatric oncology; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; HEALTH STATUS; HEALTH SURVEY; LYMPH NODE METASTASIS; MONOTHERAPY; ONCOGENE NEU; PHYSICIAN ATTITUDE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HEALTH CARE SURVEYS; HEALTH STATUS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70349434784     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0056     Document Type: Article

References (16)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemo- therapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684. (Pubitemid 41464706)
4. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract 52]. Breast Cancer Res Treat 2007.
5. Hurria A, Wong FL, Villaluna D et al. Role of age and health in treatment recommendations for older adults with breast cancer: The perspective of oncologists and primary care providers. J Clin Oncol 2008;26:5386-5392.
6. Breslow N, Clayton D. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993;88:9-25.
7. Kuss O, McLerran D. A note on the estimation of the multinomial logistic model with correlated responses in SAS. Comput Methods Programs Biomed 2007;87:262-269. (Pubitemid 47212598)
8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
9. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92: 550-556. (Pubitemid 30212316)
10. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as ad adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-5387. (Pubitemid 46623169)
11. Jones S, Holmes F, O'Shaughnessy J et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: Docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/ cyclophosphamide and is well-tolerated in women 65 or older [abstract 12]. Breast Cancer Res Treat 2007;106:S5.
12. Garrison LP Jr, Lubeck D, Lalla D et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;110:489-498.
13. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819. (Pubitemid 46657378)
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-8020. (Pubitemid 43290919)
15. Extermann M, Chen H, Cantor AB et al. Predictors of tolerance to chemotherapy in older cancer patients: A prospective pilot study. Eur J Cancer 2002;38:1466-1473. (Pubitemid 34756399)
16. Hurria A, Gupta S, ZaudererMet al. Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 2005;104:1998-2005.